College of Psychiatric and Neurologic Pharmacists

AstraZeneca Psychiatric Pharmacy Practice Award Recipient

Caroline Warnock, BSC Phm, PG Cert

Original Research

1. ANTIPSYCHOTIC UTILIZATION IN THE TREATMENT OF BIPOLAR DISORDER IN AN ACUTE CARE PSYCHIATRIC UNIT- Phillip Miller, MS, RPh, Laura L. Manzey, Pharm.D., BCPP
2. A NOVEL APPROACH TO DRUG UTILIZATION EVALUATION: USE OF PDA TECHNOLOGY TO EVALUATE THE NEW ATYPICAL ANTIPSYCHOTIC ZIPRASIDONE IN AN INPATIENT PSYCHIATRIC UNIT- Paul L. Price, Pharm.D., BCPP, Terri Craig, Pharm.D.
3. PHARMACOECONOMIC ANALYSIS OF NEWEST ATYPICAL ANTIPSYCHOTIC-ZIPRASIDONE- Lee Bufalini, Pharm.D. BCPP; Pamela Moe, Pharm.D. BCPP; Azah Borham, Pharm.D.
4. IDENTIFYING ANTIPSYCHOTIC NONADHERENCE: MEDICATION INFLUENCE AND BELIEF SURVEY- Christian Dolder, Pharm.D.; Jonathon P. Lacro, Pharm.D.; Katie Warren, R.N.; Dilip V. Jeste, M.D.
5. ECONOMICS OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC IN OLDER PSYCHOTIC PATIENTS AND IN PATIENTS WITH BIPOLAR DISORDER - WR Simons, E Yu, R Bassi
6. ANTIPSYCHOTIC-INDUCED TYPE 2 DIABETES: EVIDENCE FROM A LARGE HEALTH PLAN DATABASE - F Gianfrancesco, E Yu
7. OPTIMAL TITRATION FOR QUETIAPINE: PILOT TRIAL - Mark A. Smith, Robin McCoy, Martin Brecher
8. CONSENSUS VALIDATION OF ATYPICAL ANTIPSYCHOTIC MUE CRITERIA – Raymond C. Love, Pharm.D., BCPP, FASHP, Marie Mackowick, Pharm.D., BCPP, Dan Carpenter, Ph.D., Emalie Burks, Pharm.D., BCPP, Steven W. Stanislav, Pharm.D., BCPP
9. CLINICAL OUTCOMES WITH ATOMOXETINE IN THE MANAGEMENT OFATTENTION DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS - W. Jeffrey Brown, MS, RPh, Joachim Wernicke, M.D., Ph.D., Albert J. Allen, M.D., Ph.D., Douglas E. Fairies, Ph.D., Denai Milton, MS, David Michelson, M.D.
10. CORRELATION OF CYTOCHROME P450 1A2 ACTIVITY WITH OLANZAPINE DISPOSITION IN HEALTHY VOLUNTEERS. Kara Lee Shirley, Pharm.D., Yuen Yi Hon, Pharm.D., Scott R. Penzak, Pharm.D., Francis Y.W. Lam, Pharm.D., and Michael W. Jann, Pharm.D.
11. AN ASSESSMENT OF THE POTENTIAL FOR COMMON HERBAL SUPPLEMENTS TO CAUSE FALSE POSITIVE RESULTS ON THE ENZYME IMMUNOASSAY (EIA) URINE DRUG SCREEN John S. Markowitz, Pharm.D., C. Lindsay DeVane, Pharm.D., Jennifer Donovan, Ph.D., S.Craig Risch, M.D.·, Naresh Emmanuel, M.D.
12. GENDER DIFFERENCES IN WEIGHT GAIN AMONG ADOLESCENTS STARTED ON ATYPICIAL ANTIPSYCHOTICS - Stephen R. Saklad, Pharm.D, BCPP, Christine M. Ketchie, Pharm.D., Suchacorn Amrung, M.D., Julia E. Vertrees, Pharm.D., BCPP
13. WEIGHT AND WEIGHT-RELATED HEALTH STATUS AMONG OUTPATIENTS TREATED WITH ANTIPSYCHOTIC MEDICATIONS Daniel J. Dugan, Pharm.D., BCPP, Carlos Poston, Ph.D., Stephen Jarvis M.D., Roger W. Sommi, Pharm.D., BCPP
14. PHARMACOTHERAPY OF DEPRESSION IN WOMEN ACROSS THE REPRODUCTIVE CYCLE: FOCUS ON VENLAFAXINE - Dale R. Grothe, Pharm.D., BCPP, Dominick Albano, RPh, MBA, Jill Slater, Pharm.D., Brian Scheckner, Pharm.D., Melinda Privette, M.D.
15. LESS SWITCHING AFTER INITIAL START WITH ATYPICAL ANTIPSYCHOTICS- Gerard W.K. Hugenholtz, Eibert R. Heerdink, Willem A. Nolen, Hubert G.M. Leufkens
16. NALTREXONE EFFECTIVENESS IN TREATING SELF-ABUSE IN AN ADULT INSTITUTIONALIZED DEVELOPMENTALLY DISABLED POPULATION- Nancy C. Brahm, H. Dix Christensen; Robert C. Brown
17. MEASURING PHYSICIAN ACCEPTABILITY OF A COMPUTERIZED DECISION SUPPORT SYSTEM FOR THE TREATMENT OF DEPRESSION - Madhukar Trivedi, M.D., Tawny L. Bettinger, Pharm.D., Janet Kern, Ph.D., Bruce Grannemann, MA, Tracy M. Voegtle, MA
18. EXPLORING THE RATIONALITY OF THE ATYPICAL + TYPICAL ANTIPSYCHOTIC CO-MEDICATION STRATE - R Spencer Schaefer, Pharm.D., Jonathan P. Lacro, Pharm.D., BCPS, BCPP, Nilah Archer, RN, Annette Pozos, M.D.
19. LOSS OF SSRI EFFECTIVENESS DURING CONTINUATION OR MAINTENANCE THERAPY OF MAJOR DEPRESSION - Sophie Robert, Pharm.D., W. Alexander Morton, Pharm.D., BCPP, Elinor CG Chumney, M.Sc., Kit Simpson, Dr.P.H
20. SAFETY OF OLANZAPINE IN ADOLESCENTS: FOCUS ON CREATINE KINASE (CK) LEVELS - Julie A. Cold, Pharm.D., BCPP, Lauren G. Cottingham, Pharm.D., Sharon Sherrer, Pharm.D.
21. CLINICAL AND FINANCIAL REVIEW OF QUETIAPINE USE AT A VETERANS’ AFFAIRS MEDICAL CENTER - Richard J. Silvia, Pharm.D., BCPP, Robert Henault, RPh, CDE
22. OPTIMIZING MEDICATION ADHERENCE INTERVENTIONS FOR SCHIZOPHRENIA - Teresa J. Hudson, Pharm.D., Richard R. Owen, M.D., Xioatong Han MS, Carol Nordquist Ms, Greer Sullivan M.D., MSPH
23. ATYPICAL ANTIPSYCHOTICS: DOES IMPROVED EFFICACY AND TOLERABILITY EQUATE WITH IMPROVED QUALITY OF LIFE? - Beth M. Dubisar, Pharm.D.; Steven C. Stoner, Pharm.D., BCPP; David Vlach, M.D.
24. COST ANALYSIS OF ATYPICAL ANTIPSYCHOTICS AND CONCOMITANT PSYCHOTROPICS - Rene A. Endow, Pharm.D., BCPP, Edna O. Ng, Pharm.D., Anne-Marie Jefferson, Pharm.D., BCPP, Susan G. Leckband, RPh, BCPP, Dana N. Mazzeo, Pharm.D., Jonathan P. Lacro, Pharm.D., BCPS, BCPP
25. AN OPEN-LABEL TRIAL OF QUETIAPINE FOR ANTIPSYCHOTIC-INDUCED SEXUAL DYSFUNCTION - Matthew Byerly, M.D., Emmeline Lescouflair, M.D.

Encore Presnetations

1. COST-OUTCOMES OF RISPERIDONE VS. OLANZAPINE: A COMPUTER DATABASE AND CHART REVIEW COMPARISON AT FIVE VETERANS ADMINISTRATION SITES - Matthew Byerly, M.D., Ann Thompson, MBA, Deean Brooks, Thomas Carmody, Wilfred Acholonu, Pharm.D., Craig Karson, M.D., Michael Kashner, Ph.D., John Kuldau, M.D., Jonathan Lacro, Ph.D., Clifford Nasdahl, Pharm.D., Richard Owen, M.D.
2. RANDOM-ASSIGNMENT, DOUBLE-BLIND, CLINICAL TRIAL OF ONCE-VERSUS TWICE-DAILY ADMINISTRATION OF QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER - KR Chengappa, H Parepally, JS Brar, J Mullen, A Schilling, JM Goldstein*
3. QUETIAPINE AS ADJUNCTIVE TREATMENT FOR ADOLESCENT MANIA - MP DelBello,* ML Schwiers, HL Rosenberg, SM Strakowski
4. LONG-TERM SAFETY AND EFFICACY OF LONG-ACTING INJECTABLE RISPERIDONE - Marielle Eerdekens, M.D., N.V, Beerse, Belgium. W. Wolfgang Fleischhacker M.D., Yang Xie, Linda Beauclair, M.D., Ola Gefvert, M.D.
5. EFFICACY AND SAFETY OF A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION - John M. Kane, M.D., Marielle Eerdekens, M.D., Samuel J. Keith, M.D., Michael Lesem, M.D., Keith Karcher, MS, Jean-Pierre Lindenmayer, M.D.
6. THE PHARMACOKINETIC PROFILE OF GALANTAMINE AND RISPERIDONE WHEN ADMINISTERED ALONE AND IN COMBINATION- Qinying Zhao, Fenglei Huang, Ruth James
7. LONG-TERM EFFICACY OF GALANTAMINE IN PATIENTS WITH ALZHEIMER’S DISEASE - Murray Raskind, M.D., Elaine Peskind, M.D., Luc Truyen, M.D., Ph.D.
8. A RETROSPECTIVE REVIEW ASSESSING PATIENT FUNCTION AND ABILITY TO PARTICIPATE IN A MEDICATION-RELATED WEIGHT GAIN PREVENTION AND MANAGEMENT GROUP - Mark Schneiderhan, Pharm.D., BCPP, Melissa Holt, MS, UIC, Melissa Chu,, Susanne Chau, Maggie Lee
9. CONCOMITANT USE OF QTC PROLONGING DRUGS IN PERSONS WITH SCHIZOPHRENIC OR BIPOLAR DISORDERS - H. Ascher-Svanum, J. S. Kennedy, D. Lee, M. Haberman, S. Foster, M. Keith
10. ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING INDIVIDUALS WITH SCHIZOPHRENIA FROM RISPERIDONE TO OLANZAPINE - Zhongyun Zhao, Ph.D., Madhav Namjoshi, Ph.D., Beth Barber, Ph.D., Danielle Loosbrock, M.H.A., Jacqui Pesa, Ph.D., Sandra Tunis, Ph.D., Michael Keith, Pharm.D., Alan Breier, M.D.
11. ACUTE RESPONSE TO OLANZAPINE PREDICTS CONTINUED IMPROVEMENT IN SCHIZOPHRENIA - Bruce J. Kinon, M.D., Zhongyun Zhao, Ph.D., Beth L. Barber, Ph.D., Heidi S. Wirtz, MS, Pharm.D.
12. OLANZAPINE VERSUS DIVALPROEX SODIUM FOR THE TREATMENT OF ACUTE MANIA AND MAINTENANCE OF REMISSION: A 47-WEEK STUDY - Mauricio Tohen; Robert W Baker; Lori Altshuler; Carlos A. Zarate; T Suppes; T.A. Ketter; Starr Grundy; and Leslie Schuh
13. IM OLANZAPINE: PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE - Stacy David, Ph.D., Richard F. Bergstrom, Ph.D., Vivian L. Bruner, M.S., Alan Brier, M.D., Heidi Wirtz, Pharm.D. and Malcolm I. Mitchell, M.D.
14. A RETROSPECTIVE COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED KINGDOM - Kenneth Kwong, M.D., Ph.D., MBA, Kenneth Hornbuckle, DVM, Ph.D., Patrizia Cavazzoni M.D., Alan Breier, M.D., James Kotsanos, M.D. MPH, Pat Toalson, RPh, Jasmanda Wu MPH, and Rury Holman M.D.
15. EFFECTIVENESS OF RAPID INITIAL DOSE ESCALATION OF ORAL OLANZAPINE FOR ACUTE AGITATION - Robert W. Baker, M.D.; Bruce J. Kinon, M.D.; Hong Liu, Ph.D.; Angela Richey, RPh; Angela L. Hill, Pharm.D.; Richard F. Bergstrom, Ph.D., Virginia Stauffer, Pharm.D., BCPS and Leslie M. Schuh, Ph.D.
16. EFFICACY AND SAFETY OF ARIPIPRAZOLE AND HALOPERIDOL VERSUS PLACEBO IN SCHIZOPHRENIA - Heidi Liston, Pharm.D. Anutosh R. Saha, Ph.D., Mirza W. Ali, Ph.D., Gary Ingenito, M.D., Ph.D., Geoffrey C. Dunbar M.D., William H Carson, M.D.
17. ARIPIPRAZOLE AND RISPERIDONE VERSUS PLACEBO IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER – L Bailey, RD McQuade, M Kujawa, WH Carson, A Saha, M Ali
18. GABAPENTIN USE IN A MEDICAID POPULATION - Ann M. Hamer, Pharm.D., Dean Haxby, Pharm.D., Bentson H. McFarland, M.D., Kathy Ketchum, RPh
19. ANTIEPILEPTIC DRUG TREATMENT OF NEUROBEHAVIORAL SYMPTOMS ASSOCIATED WITH BRAIN INJURY - Sara G. Augustin, Pharm.D., BCPP, John R. Sass, Ph.D., Paula Barrett, LCSW, Richard G. Lambert, Ph.D., ED.S
20. SUCCESSFUL TREATMENT OF DELIRIUM WITH RISPERIDONE: A CASE SERIES - Dinesh Mittal, M.D.; Nita Jimmerson, RN; William D. Johnson, Ph.D., Richard Kennedy, M.D.; Rafael Torres, M.D., Henry Nasrallah, M.D.
21. POSSIBLE INTERACTION BETWEEN ZOPICLONE AND NEFAZODONE - Chris Alderman, Markus Gebauer, Andy Gilbert, John Condon
22. IMPACT OF CLOZAPINE VERSUS HALOPERIDOL ON CONDITIONAL RELEASE TIME AND RATES OF REVOCATION IN A FORENSIC PSYCHIATRIC POPULATION - Steven C. Stoner, Pharm.D., BCPP; Jessica Wehner Lea, Pharm.D.; Beth Dubisar, Pharm.D.; Kathleen Roebuck-Colgan, BA, RN; David Vlach
23. EXPERIENCE WITH SWITCHING PATIENTS TO ZIPRASIDONE FROM OTHER ANTIPSYCHOTICS - Dee Ann Estes, Pharm.D., BCPP, MPA
24. MEDICATION CONTROL ISSUES IN BORDERLINE PERSONALITY DISORDERS - Karen Moeller, Eugene Makela, Jennifer Schumacher
25. A COMPARISON OF TYRAMINE SENSITIVITY BETWEEN THE SELEGILINE TRANSDERMAL SYSTEM (STS) AND ORAL SELEGILINE - Chad M. VanDenBerg, Pharm.D., Lawrence F. Blob, M.D.; Eva M. Kemper, Melvin Sharoky, M.D.; Albert J Azzaro, Ph.D.
26. STRATEGIES TO IMPROVE PSYCHIATRIC MEDICATION USE IN PRIMARY CARE SETTINGS - Stimmel, GL; Aiso, JY
27. OLANZAPINE IMPROVES TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA – Ginny Stauffer, Pharm.D., Bruce J. Kinon, M.D., Lynn Wang, M.S., Khanhn T. Thi, Pharm.D.

Work in Progresss

1. AN EXAMINATION OF DRUG-RELATED PROBLEMS AMONG PERSONS TREATED IN A COMMUNITY MENTAL HEALTH FACILITY - Jessica W. Lea, Pharm.D., Roger W. Sommi, Pharm.D., BCPP, Daniel J. Dugan, Pharm.D., BCPP
2. TOPIRAMATE TREATMENT AND THYROID FUNCTION - Heather Alexander, Jessica L. Goren, Pharm.D., BCPP
3. AN EXAMINATION COMPARING DEPOT ANTIPSYCHOTIC USE TO ORAL ANTIPSYCHOTIC IN OUTPATIENTS TREATED FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER - Naomi A House, Pharm.D, BCPP, Daniel Dugan, Pharm.D., BCPP, Roger W. Sommi, Pharm.D., BCPP
4. PILOT STUDY TO INVESTIGATE TREATMENT OUTCOMES BY SUBJECTIVE ANTIDEPRESSANT RESPONSE - Michelle Poon, Michael Luhm , L. Tornatore, Pharm.D., M.S
5. ATYPICAL ANTIPSYCHOTIC DRUG USE IN 16 QUEBEC HOSPITALS- Germain Legault, Pierre Arseneault Md Ph.D. , Jean-Pierre Pellerin Ph.D.